Novartis Investor Presentation

New Novartis: Our strategy Our focus Our priorities Improved financials Launch excellence > High-value innovation Operational excellence Strengthen foundations Conclusion Abbreviations 3. High-value innovation Potential positive NATALEE readout offers significant upside to sales growth KisqaliⓇ Ph3 OS results in 1L mBC MONALEESA-2 Median OS Risk reduction 24% 63.9 months1 NATALEE adjuvant study Ribociclib 400mg/day 3 weeks on/1 week off RIB+ 36 months (-39 cycles) 36 months 60 months To date not reached first interim; expect filing in 2023 23 HR++HER2-eBC ET MONALEESA-7 R Pre- and post- menopausal 1:1 Risk reduction 24% 58.6 months2 Anatomic Stage II & III N=5000 ET MONALEESA-3 Risk reduction 33% 67.6 months3 NSAI 60 months [+ goserelin in pre-menopausal women & men] 60 months Indication Early breast cancer NSAI 60 months [+ goserelin in pre-menopausal women & men] Potential Population DOO >USD 1bn O >USD 2bn >USD 3bn ■ Proven OS benefit across all three Phase 3 clinical trials ☐ ■ Same OS benefit regardless of menopausal status, hormone therapy partner, or dose modifications4 ■ Maintains clinical benefit even after prior CDK4/6i use5 Fully enrolled as of April 2021 Primary analysis planned at 500 iDFS events, expected in 2023 Interim analyses at 70% and 85% 218K (US & EU)6 1. In months vs. vs 51.4, P value: 0.008. Reference: Hortobagyi, GN et al., 2022 2. vs 51.8. Reference: Lu, YS et al., 2022 3. vs 51.4. Reference: Neven, P et al., 2022 4. Based on an analysis of MONALEESA-2, -3 and -7 the MAINTAIN IIT, Patients who received Kisqali and changed their ET in 2L had PFS twice as long as patients who only changed their ET 6. eBC Patient - Adjuvant Breast Cancer Opportunity Assessment June 2020 5. Based on Novartis Investor Presentation | September 22, 2022 1 | NOVARTIS | Reimagining Medicine

View entire presentation